Stockscreener 앱 받기
8.983
4.94%
0.423
시간 외 거래:
8.95
-0.033
-0.37%
전일 마감가:
$8.56
열려 있는:
$8.52
하루 거래량:
34,719
Relative Volume:
0.97
시가총액:
$28.55M
수익:
-
순이익/손실:
$-68.80M
주가수익비율:
-7.6778
EPS:
-1.17
순현금흐름:
$-59.06M
1주 성능:
+5.43%
1개월 성능:
+25.76%
6개월 성능:
+2,328%
1년 성능:
+1,347%
1일 변동 폭
$8.125
$9.12
1주일 범위
$7.13
$9.12
52주 변동 폭
$0.257
$9.90
Passage Bio Inc Stock (PASG) Company Profile
명칭
Passage Bio Inc
전화
(267) 866-0312
주소
ONE COMMERCE SQUARE, PHILADELPHIA, PA
PASG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
8.983 | 27.21M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-29 | 재개 | Wedbush | Outperform |
| 2024-09-03 | 개시 | Rodman & Renshaw | Buy |
| 2022-03-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-19 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-07-01 | 개시 | Raymond James | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-03-04 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-02-04 | 개시 | Guggenheim | Buy |
| 2021-01-25 | 개시 | Wedbush | Outperform |
| 2021-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 개시 | Citigroup | Neutral |
| 2020-08-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2020-03-24 | 개시 | Cowen | Outperform |
| 2020-03-24 | 개시 | Goldman | Buy |
| 2020-03-24 | 개시 | JP Morgan | Overweight |
모두보기
Passage Bio Inc 주식(PASG)의 최신 뉴스
Lucid Capital Markets initiates Passage Bio stock with Buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Passage Bio stock with Buy rating - Investing.com India
Will Salona Cotspin Limited Benefit From Broader Market BounceLow Risk Investment Ideas & Maximize Gains Professionally - earlytimes.in
Passage Bio (PASG) Price Target Decreased by 45.15% to 33.15 - MSN
How Passage Bio Inc. stock compares to market leadersInsider Selling & AI Powered Market Trend Analysis - newser.com
Is Passage Bio Inc. stock bottoming out2025 Volatility Report & Proven Capital Preservation Tips - newser.com
Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates - MSN
How Passage Bio Inc. stock reacts to Fed rate cuts2025 Momentum Check & Low Risk High Win Rate Picks - newser.com
Applying chart zones and confluence areas to Passage Bio Inc.2025 Bull vs Bear & Safe Swing Trade Setups - newser.com
What momentum shifts mean for Passage Bio Inc.July 2025 Technicals & Safe Entry Trade Reports - newser.com
Chardan Capital Expects Reduced Earnings for Passage Bio - Defense World
Passage Bio Inc. stock trendline breakdownWeekly Trade Recap & Weekly Return Optimization Alerts - newser.com
Ranking Passage Bio Inc. among high performing stocks via toolsQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Passage Bio, Inc.Common Stock (NQ: PASG - FinancialContent
Using economic indicators to assess Passage Bio Inc. potentialQuarterly Earnings Report & Technical Confirmation Trade Alerts - newser.com
How Passage Bio Inc. stock reacts to global recession fearsEarnings Miss & Real-Time Volume Triggers - newser.com
Passage Bio Inc Stock Analysis and ForecastREITs Market Trends & Low Cost Wealth Plans - earlytimes.in
Chardan Capital Raises Passage Bio (NASDAQ:PASG) Price Target to $21.00 - Defense World
Passage Bio (NASDAQ:PASG) Price Target Raised to $21.00 - Defense World
Is Passage Bio Inc. stock a contrarian buyJuly 2025 Final Week & Weekly Stock Breakout Alerts - Fundação Cultural do Pará
What is Wedbush’s Forecast for Passage Bio FY2025 Earnings? - Defense World
Will Passage Bio Inc. price bounce be sustainableJuly 2025 Summary & Low Risk High Reward Ideas - newser.com
Why Passage Bio Inc. stock could rally in 2025Weekly Trend Recap & Stock Portfolio Risk Control - newser.com
Why Passage Bio Inc. stock remains a top recommendationEarnings Growth Report & Low Drawdown Investment Ideas - newser.com
Chardan Capital Raises Price Target on Passage Bio (PASG) to $21 - GuruFocus
Chardan Raises Price Target on Passage Bio to $21 From $6, Keeps Buy Rating - MarketScreener
3 Best Biotech Stocks to Buy Now, 11/12/2025, According to Top Analysts - TipRanks
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF) and Passage Bio (PASG) - The Globe and Mail
Passage Bio Cuts Losses And Gains Analysts’ Confidence - Finimize
PASSAGE BIO, INC. Q3 Loss Decreases, Beats Estimates - Nasdaq
Passage Bio (PASG) Advances PBFT02 Clinical Trials and FDA Discu - GuruFocus
[10-Q] Passage BIO, Inc. Quarterly Earnings Report | PASG SEC FilingForm 10-Q - Stock Titan
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Passage Bio Q3 net loss narrows to $7.7 mln - MarketScreener
Passage Bio, Inc. Announces Active Enrollment in upliFT-D Study and Regulatory Alignment with FDA - Quiver Quantitative
PASG: Clinical trial progress, reduced net loss, and strong cash position support future milestones - TradingView
[8-K] Passage BIO, Inc. Reports Material Event | PASG SEC FilingForm 8-K - Stock Titan
Passage Bio (NASDAQ: PASG) narrows net loss to $7.7M, y/y from $19.3M as costs decline - Stock Titan
Passage Bio Inc (PASG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
1.88%
자본화:
|
볼륨(24시간):